Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Effect of dosage of 17ß-estradiol on uterine growth in Turner syndrome - a randomized controlled clinical pilot trial

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Longitudinal Increases in Serum Insulin-like Factor 3 and Testosterone Determined by LC-MS/MS in Pubertal Danish Boys

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Marked Increase in Incident Gynecomastia: A 20-Year National Registry Study, 1998 to 2017

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Oral D/L-3-Hydroxybutyrate stimulates cholecystokinin and insulin secretion and slows gastric emptying in healthy males

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Apolipoprotein M and risk of type 2 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Disease Control and Gender Predict the Socioeconomic Effects of Acromegaly: A Nationwide Cohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. A distinctive epigenetic ageing profile in human granulosa cells

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Unaffected bone mineral density in Danish children and adolescents with type 1 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Bone turnover markers during the remission phase in children and adolescents with type 1 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

CONTEXT: Most Turner syndrome (TS) girls need exogenous estrogen treatment to induce puberty and normal uterine growth. After puberty, the optimal estrogen treatment protocol has not been determined.

OBJECTIVE: To compare 2 doses of oral 17ß-estradiol on uterine size.

DESIGN: A double-blind, 5-year randomized controlled clinical trial.

SETTING: Ambulatory care.

PARTICIPANTS: Twenty young TS women (19.2 ± 2.5 years, range 16.0-24.9) participated. Sixteen patients completed the study. No patients withdrew due to adverse effects.

INTERVENTION: The lower dose (LD) group took 2 mg 17ß-estradiol/d orally and placebo. The higher dose (HD) group took 4 mg 17ß-estradiol/d orally.

MAIN OUTCOME MEASURE(S): Uterine volume evaluated by transabdominal ultrasound yearly.

RESULTS: Uterine size increased significantly more in the HD group compared with the LD group (P = 0.038), with a gain in uterine volume within the first 3 years of treatment of 19.6 mL (95% confidence interval [CI] = 4.0-19.0) in the HD group compared with 11.5 mL (95% CI = 11.2-27.9) in the LD group. The difference in 3-year gain was 8.1 mL (95% CI = 0.7-15.9). At the last visit, there were no significant differences in uterine volume between the groups.

CONCLUSION: HD oral 17ß-estradiol induces a steeper increase in uterine volume within the first years of treatment compared with the LD. However, the uterine growth potential seems to be the same in most young TS women making the duration of treatment equally significant as estrogen dose, although a few TS women did not experience sufficient uterine growth on 2 mg of estradiol.

CLINICALTRIALS.GOV: NCT00134745Abbreviations: BMI, body mass index; BSA, body surface area; DHEAS, dihydroepiandrosteronesulfate; HD, higher dose; HRT, hormone replacement therapy; LD, lower dose; TS, Turner syndrome; US, ultrasound.

Original languageEnglish
Article numberdgz061
JournalThe Journal of clinical endocrinology and metabolism
Volume105
Issue number3
Pages (from-to)1-10
ISSN0021-972X
DOIs
Publication statusPublished - 1 Mar 2020

ID: 58139124